Sumatriptan pills 50mg, 2pcs

Composition

1 film-coated tablet contains: sumatriptan succinate 140 (70) mg, in terms of sumatriptan 100 (50) mg.

Auxiliary substances:

hyprolose (hydroxypropylcellulose Klucel LF),

calcium hydrophosphate dihydrate,

mannitol (mannitol),

magnesium stearate,

croscarmellose sodium (primellose),

microcrystalline cellulose.

Composition of the film shell:

selekout AQ-02003 (hypromellose (hydroxypropylmethylcellulose),

macrogol (polyethylene glycol 6000),

titanium dioxide).

Pharmacological action

Sumatriptan is an anti-migraine drug. It is a specific and selective agonist of 5-HT-1 serotonin receptors located mainly in the blood vessels of the brain, and does not act on other subtypes of 5-HT-serotonin receptors (5-HT 2-7).

Causes vasoconstriction of the carotid arterial bed, which supplies blood to extracranial and intracranial tissues (vasodilation of the meninges and / or their edema is the main mechanism of migraine development in humans), without significantly affecting the cerebral blood flow.

Inhibits the activity of receptors of the endings of the afferent fibers of the trigeminal nerve in the dura mater (as a result, the release of sensory neuropeptides decreases). Eliminates nausea and photophobia associated with a migraine attack.

In 50-70% of cases, it quickly eliminates an attack when taken orally at a dose of 25-100 mg. Within 24 hours,1/3 of cases may develop a relapse that requires repeated use. The action starts in 30 minutes. After oral use at a dose of 100 mg.

Indications

Relief of migraine attacks with or without aura.

Contraindications

-Hypersensitivity.

– Hemiplegic, basilar or ophthalmoplegic forms of migraine.

– Coronary heart disease (CHD) and suspected it.

– Angina pectoris (including Prinzmetal angina pectoris).

– Myocardial infarction (including in the anamnesis).

– Arterial hypertension (uncontrolled).

– Occlusive diseases of the peripheral arteries.

– Stroke or transient cerebrovascular accident (including in the anamnesis).

– Hepatic and / or renal insufficiency.

Use with caution:

– Epilepsy (including any conditions with a reduced epileptic threshold).

– Arterial hypertension (controlled).

Pregnancy and lactation. – Children and teenagers under 18 years of age. – Older than 65 years of age. – Concomitant use of drugs containing ergotamine and its derivatives, as well as MAO inhibitors, and a period of up to 14 days after their withdrawal.

Side effects

From the cardiovascular system: decrease in blood pressure, transient increase in blood pressure (observed shortly after use), bradycardia, palpitation, tachycardia (including ventricular); in some cases-severe cardiac arrhythmias (up to ventricular fibrillation), transient ECG changes of the ischemic type, myocardial infarction; in isolated cases-Raynaud’s syndrome.

From the digestive system: nausea and vomiting; in some cases-a slight increase in the activity of “hepatic” transaminases, abdominal discomfort, dysphagia, ischemic colitis.

Nervous system disorders: dizziness, weakness (usually mild or moderate and transient); rarely-drowsiness, fatigue (more often when taken orally); in some cases-epileptic seizures (usually with a history of epilepsy).

From the side of the senses: diplopia, flickering of flies in front of the eyes, nystagmus, scotoma, decreased visual acuity (may be associated with the migraine attacks themselves).

Allergic reactions: skin rash (including urticaria and erythematous rashes), itchy skin, anaphylactic reactions. Other services: myalgia, “hot flashes” of blood to the face.

Interaction

When administered concomitantly with ergotamine and ergotamine-containing drugs, prolonged vascular spasm is possible (the interval between their use should be at least 24 hours).

Interaction between sumatriptan and MAO inhibitors is possible (decrease in the intensity of sumatriptan metabolism, increase in its concentration).

With the simultaneous use of sumatriptan and drugs from the group of selective serotonin reuptake inhibitors, weakness, hyperreflexia and impaired coordination of movements may develop.

How to take, course of use and dosage

– Hypersensitivity.

– Hemiplegic, basilar or ophthalmoplegic forms of migraine.

– Coronary heart disease (CHD) and suspected it.

– Angina pectoris (including Prinzmetal angina pectoris).

– Myocardial infarction (including in the anamnesis).

– Arterial hypertension (uncontrolled).

– Occlusive diseases of the peripheral arteries.

– Stroke or transient cerebrovascular accident (including in the anamnesis).

– Hepatic and / or renal insufficiency.

Use with caution:  – Epilepsy (including any condition with a reduced epileptic threshold).

– Arterial hypertension (controlled).

Pregnancy and lactation. – Children and teenagers under 18 years of age. – Older than 65 years of age. – Concomitant use of drugs containing ergotamine and its derivatives, as well as MAO inhibitors, and a period of up to 14 days after their withdrawal.

Overdose

Symptoms:

when taken orally up to 400 mg, no other side effects are observed, except for those listed above.

Treatment:

observation of the patient for 10 hours, symptomatic therapy.

Special instructions

It is not intended for the prevention of migraines (use during a migraine aura before other symptoms occur may not prevent the development of headaches).

If there is no effect on the first dose, the diagnosis should be clarified. It should be borne in mind that patients suffering from migraines are at risk of developing a stroke or transient disorders of the cerebral circulation. When prescribed during lactation, it is not recommended to breastfeed the child within 24 hours after taking sumatriptan. Patients with hypersensitivity to sulfonamides with the introduction of sumatriptan have an increased risk of allergic reactions (from skin manifestations to anaphylactic shock).

Patients at risk from the cardiovascular system should not start therapy without a preliminary examination (women in the postmenopausal period, men over the age of 40, people with risk factors for coronary heart disease).

Before prescribing sumatriptan to patients with newly diagnosed or atypical migraines, other potentially dangerous neurological diseases should be excluded.

The experience of using sumatriptan in patients over 65 years of age is limited (there is no significant difference in pharmacokinetics compared to younger patients).

Application when driving vehicles: during the treatment period, care should be taken when driving vehicles and engaging in other potentially active activities that require increased concentration of attention and speed of psychomotor reactions.

Storage conditions

Store in a dry place protected from light at a temperature not exceeding 25°C.

Shelf life

2 years

Active ingredient

Sumatriptan

Conditions of release from pharmacies

By prescription

Dosage form

Tablets